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OBJECTIVES: Glaucoma is a condition affecting one 
or both eyes with raised intraocular pressure (IOP). IOP
reduction can prevent or slow progression of visual ﬁeld
loss. The objective of the analysis was to investigate the
four-year costs of bimatoprost 0.03% as an alternative to
ﬁltration surgery (FS) for glaucoma patients on maximum
tolerable medical therapy (MTMT) in Italy. METHODS:
A Markov model with monthly cycles based on effec-
tiveness and resource-use data from a clinical trial and
expert statements was designed. The trial covered 83
patients on MTMT. The model compared bimatoprost
with FS. In one model-arm patients began treatment with
bimatoprost. If a 30% reduction in IOP was not reached
using mono-therapy the patient proceeded with combi-
nation-therapy and eventually FS. In the other model-arm
FS was performed after the ﬁrst ophthalmologist visit. In
both arms treatment changes involved additional follow-
up visits besides the scheduled, an increasing proportion
needed pressure-lowering medication after FS and 40%
were operated in both eyes. Unit costs were obtained from
an Italian chart and tariffs review. The model analysed
four-year costs from a national Health care sector per-
spective. A 5% discount rate was used. RESULTS: The
4-year cost per patient in the bimatoprost arm was €3372
with visit costs and medications contributing the most. In
the FS arm four years costs were €4284 with the costs
being driven by primary surgery, secondary surgery, and
pressure-lowering medications needed post-surgery to
control IOP. CONCLUSIONS: The analysis indicates that
bimatoprost over a four year horizon is a cheaper alter-
native than FS. This result was strengthened by a thresh-
old sensitivity analysis showing that the FS price would
need to be reduced 73% before FS and bimatoprost were
equally costly. Italian ophthalmologists should therefore
consider bimatoprost as an alternative to FS.
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OBJECTIVE: The purpose of this study was to determine
the burden of illness of inﬂuenza in the United States.
METHODS: Retrospective analysis was conducted of the
1999 portion of the Medical Expenditure Panel Survey.
Data was collected from a nationally representative
sample of 24,618 respondents and linked to data from
respondents’ medical care and health insurance providers
and employers. Data used in this study included medical
conditions, use and payments for medical care, and
employment information comprised of hourly earnings,
hours worked, and disability days. Inﬂuenza patients
were identiﬁed using ICD-9-CM codes (487.0–487.8).
Direct costs were calculated using patient and third-party
payments for inﬂuenza-related medical events. Indirect
costs were calculated for inﬂuenza patients who incurred
missed workdays using the human capital approach.
Sample estimates were weighted and projected to the pop-
ulation and 95 percent conﬁdence limits were calculated
using the Taylor expansion method. RESULTS: Ap-
proximately 6.38% (95% C.L. = 5.86%–6.91%) or
17,640,761 individuals experienced inﬂuenza and 2.50%
(95% C.L. = 2.22%–2.79%) or 6,920,976 individuals
experienced inﬂuenza resulting in missed workdays. Total
costs of inﬂuenza were $10,413,397,186. Direct costs
were $1,251,588,028. Ofﬁce-based medical provider
visits represented the highest proportion of direct 
costs, at $407,049,515 (mean = $64.56; 95% C.L. =
$54.45–$74.67). Home health care expenditures were
$265 million. Expenditures for inpatient stays, prescrip-
tion medications, and emergency department visits were
similar, at $189 million, $185 million, and $175 million,
respectively. Outpatient services represented the lowest
proportion of direct costs, at $31 million. Indirect costs
of inﬂuenza were $9,161,809,158 with mean indirect
costs of $1,325 per patient (95% C.L. = $1,130–$1,521).
CONCLUSIONS: Affecting more than 17 million indi-
viduals in the population with a total cost of $10.4
billion, the burden of illness of inﬂuenza was substantial.
With indirect costs accounting for nearly 90% of total
costs, inﬂuenza signiﬁcantly impacts the labor force
underscoring the importance of prevention to minimize
absenteeism and maintain productivity.
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OBJECTIVE: Placement of a biliary stent (plastic or
metal) is a recognised palliative treatment for malignant
biliary obstruction. Metallic stents have a lower occlusion
rate and avoid reinterventions for exchange but are more
expensive. The objective of this analysis is to compare the
total costs at one year of metal versus plastic stent place-
ment. METHODS: A Markov model with a time horizon
